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1. Introduction 
1.1 Genes associated with T2DM  
1.1.1 Genes associated with ion transport 
1.1.1.1 KCNJ11 
The potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) gene encodes 
Kir6.2 protein, the inwardly rectifying potassium channel, which is a complex of two 
subunits [2]. ATP-sensitive K+ (KATP) channels critically control insulin secretion by coupling 
metabolism to electrical activity [3]. The ǃ-cell channels are assembled, with tetradimeric 
stoichiometry, from two structurally distinct subunits: inwardly rectifying K-channel 
subunit (KIR6.2) and the regulatory sulfonylurea receptor subunit-1 (SUR1).  Some studies 
showed that the KCNJ11 E23K (Lys23Glu, 67 G>A, rs5219) polymorphism could affect 
insulin secretion and T2DM susceptibility by influencing the sensitivity of the KATP channel 
to ATP [4-6]. E23K promotes development of T2DM by increasing the threshold ATP 
concentration, thus inducing over activity of pancreatic ǃ-cell KATP channels and inhibiting 
insulin secretion [7]. E23K markedly affected channel gating, significantly reduced the time 
spent in long inter burst closed states. Meta-analysis of all case-control data showed that the 
E23K allele was associated with T2DM [8]. The E23K variant was associated with a 
reduction in estimates of glucose-induced serum insulin levels in middle-aged glucose-
tolerant subjects. This result is in accordance with the recent in vitro finding that the E23K 
variant is associated with a reduced ATP sensitivity of the Kir6.2/SUR1channel complex [4, 
7]. T2DM patients with one A allele of the KCNJ11 E23K polymorphism seem to be more 
sensitive to repaglinide as compared with individuals with the GG genotype [9]. 
1.1.1.2 KCNQ1 
KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 1) gene, locates on 
11p15.5, encodes a voltage-gated K+ channel with six transmembrane regions and is 
expressed in the heart, stomach, small and large intestine, kidney and pancreas [10]. Two 
independent GWA studies identified that SNPs rs2237892, rs2237895, and rs2237897 located 
in intron 15 of the KCNQ1 gene were strongly associated with T2DM [6,7]. The association 
www.intechopen.com
Recent Advances in the Pathogenesis, Prevention and  
Management of Type 2 Diabetes and its Complications 
 
414 
of rs2237892, rs2237897, and rs2283228 with T2DM was confirmed in populations of Korean, 
Singaporean, Chinese, European ancestry and Japanese. The risk allele of rs2237892, 
rs2237895, and rs2237897 were associated with impairment of insulin secretion according to 
the homeostasis model assessment of ǃ-cell function or the corrected insulin response [11, 
12]. In a Chinese study, SNP rs2237892 was significantly associated with increasing fasting 
plasma glucose, while rs2237892 and rs2237897 were associated with HbA1c. The SNP 
rs2237897 was associated with both acute insulin and C-peptide response after arginine 
stimulation in T2DM group. The SNP rs2237895 was associated with both first- and second-
phase insulin secretions in the controls. For rs2237892, rs2237895 and rs2237897 
polymorphisms, homozygous carriers of the diabetes-associated allele had significantly 
decreased BMI (body mass index) and waist circumferences [13]. In German population, the 
rs2237892, rs2237895 and rs2237897 were nominally associated with OGTT (oral glucose 
tolerance test)-derived insulin secretion indexes [14]. It has been reported that SNP 
rs2237892 affected repaglinide and rosiglitazone therapeutic response. Individuals who 
were rs2237892 TT homozygote carriers treated with repaglinide for 48 weeks exhibited 
lower 2-h glucose levels and significantly higher cumulative attainment rates of target 2-h 
glucose levels than the C allele carriers; patients with a greater number of rs2237892 C 
alleles showed larger augmentations in both fasting insulin and HOMA-IR. The rs2237895 C 
allele was also associated with greater increments in both fasting insulin and HOMA-IR. 
SNP rs2237897 associated with decrease in 2-h glucose levels in the rosiglitazone 48-week 
therapy [15]. The minor C-allele of rs2237895 of KCNQ1 gene, which had a prevalence of 
about 42% among Caucasians was associated with reduced measures of insulin release 
following an oral glucose load suggesting that the increased risk T2DM [16]. Another SNP 
rs151290 was associated with 30-min C-peptide levels during OGTT, first-phase insulin 
secretion, and insulinogenic index after adjustment in the dominant model in the population 
of mainland China [17]. And rs151290 was associated with glucose-stimulated gastric 
inhibitory polypeptide and GLP-1 increase after adjustment in the dominant model [14]. The 
molecular mechanism of KCNQ1 SNPs in the intron affects insulin secretion is unclear 
[6,8,9], suggesting the important role of KCNQ1 in insulin secretion by pancreatic ǃ-cells. 
The increased risk for T2DM associated with KCNQ1 is likely to be caused by a reduction in 
insulin secretion. Further studies will be needed to verify these findings and to fully 
delineate the role of KCNQ1 and its related pathways in disease pathogenesis [18] . 
1.1.1.3 SLC30A8 
GWA studies also identified that the zinc transporter solute carrier family 30 member 8 gene 
(SLC30A8) polymorphism was a risk of T2DM in several populations [19-25]. The SLC30A8 
gene is an especially interesting candidate gene because of its exclusive expression in the 
pancreas and major in ǃ-cell [25, 26]. SLC30A8 gene encodes ion channel zinc transporter 
protein member 8 (ZnT-8), which is thought to be the ǃ-cell zinc concentration regulator. 
ZnT-8 is a critical molecule during the insulin maturation and release process that carries 
zinc from the cytoplasm into insulin secretory vesicles [26]. Therefore, its polymorphisms 
may affect its activity, which in turns correlates with T2DM susceptibility and therapeutic 
efficacy. SNP rs13266634 polymorphism (973C>T) in SLC30A8 gene is a non synonymous 
SNP that causes an amino acid change from arginine (R) to tryptophan (W) at position 325 
(Arg325Trp). This SNP is associated with T2DM onset and development in several 
populations [19-25]. It has been reported that the genetic polymorphism of SLC30A8 was 
associated with impaired proinsulin conversion involved in the production and secretion 
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pathway [27]. Fu et al. found that reduced ZnT-8 expression in cultured pancreatic ǃ cells 
gives rise to reduced insulin response to hyperglycemia and that SLC30A8 polymorphism 
could affect insulin secretion and glycemic response [28]. Another two studies indicated that 
patients with the rs13266634 C allele showed decreased first-phase insulin release following 
an intravenously administered glucose load [29, 30]. Furthermore, it has been found that the 
C alleles of rs13266634 at SLC30A8 were associated with increased FPG and decreased 
insulin during the OGTT. An investigation also showed SNP rs13266634 increased the risk 
for T2DM by 1.24-fold in Chinese Han population [30]. A Chinese population study 
explored SLC30A8 is one susceptibility gene for T2DM and influences response to 
repaglinide.  T2DM patients with T allele showed a better repaglinide response on FINS and 
PINS compared with CC wild-type homozygote [31].  
1.1.1.4 WSF1 
Wolfram syndrome 1 (WFS1) gene encodes wolframin, a 100 kDa transmembrane 
glycoprotein that maintains calcium homeostasis of the endoplasmic reticulum, which is 
expressed in neurons and pancreatic ǃ-cells and regulates calcium fluxes in the endoplasmic 
reticulum [32]. WFS1 is critical for survival and function of insulin-producing pancreatic ǃ-
cells [33]. WFS1 gene polymorphism rs10010131 was confirmed with T2DM in several GWA 
studies [19-25]. In the Diabetes Prevention Program, it is noted a trend towards increased 
insulin secretion in carriers of the protective rs10010131 variants [34]. Rare mutations in 
WFS1 cause Wolfram syndrome, variation in WFS1 also predisposes to common T2DM. It 
has been reported that WFS1 gene variants were associated with reduced insulin response to 
oral but not intravenous glucose [35-39]. WFS1 gene was associated with estimates of a 
decreased pancreatic ǃ-cell function among middle-aged individuals with abnormal glucose 
regulation [37]. WFS1 gene was also associated with impaired incretin signaling, the level of 
glycemia determines SNP effects on insulin secretion. This indicated the increasing 
relevance of these SNPs during the progression of prediabetes stages toward clinically overt 
T2DM [40]. 
1.1.2 Genes involved in cell cycles 
1.1.2.1 CDKAL1 
A variant in the cyclin-dependent kinase 5 (CDK5) regulatory subunit associated protein 
1-like 1 (CDKAL1) gene was associated with T2DM in individuals of European ancestry 
and individuals from Hong Kong of Han Chinese ancestry [22]. SNP rs7756992 is located 
in intron 5 of the CDKAL1. It resides in a large LD block of 201.7 kb that includes the 
CDKAL1 gene exons 1-5 and the minimal promoter region but no other known genes. It 
has been proposed that polymorphism rs7756992 confers risk of T2DM through reduced 
insulin secretion because the insulin response for heterozygote was approximately 20% 
lower than for heterozygote or non carriers. The function of the CDKAL1 gene product is 
still unknown. But the CDKAL1 gene product is similar to CDK5 regulatory subunit-
associated protein 1 (CDK5RAP1) gene product. CDK5RAP1 is expressed in neuronal 
tissues and inhibits CDK5 activity by binding to the CDK5 regulatory subunit p35. In 
pancreatic ǃ-cells, CDK5 shows to act in the loss of ǃ-cell function under glucotoxic 
conditions [41]. Inhibition of the CDK5/p35 complex prevents a decrease of insulin gene 
expression and glucotoxicity [42]. It is proposed that CDKAL1 may act in the inhibition of 
the CDK5/p35 complex in ǃ-cells similar to CDK5RAP1 in neuronal tissue. Reduced 
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CDKAL1 expression or inhibitory function could lead to an impaired response to 
glucotoxicity. The association of CDKAL1 rs7756992 with T2DM was replicated in 
Japanese [43], Chinese [30] and Indians populations [44]. And variants in CDKAL1 were 
strongly associated with ǃ-cell function estimated by HOMA-ǃ (Homeostasis model 
assessment for ǃ cell function) [30]. Evidence from previous GWA studies implicating 
variants in CDKAL1 and near CDKN2A/B implies that cell cycle dysregulation may be a 
common pathogenetic mechanism in T2DM [19, 20, 24].  
1.1.2.2 CDKN2A/B 
Cyclin-dependent kinase inhibitor-2A/B (CDKN2A/B) gene encode p15INK4b and p16INK4a 
protein which are tumor suppressors that inhibit cyclin-dependent kianse 6 (CDK6) and 
CDK4, respectively. CDKN2B and CDKN2A are expressed in pancreatic islets and 
adipocytes [19, 20, 24]. CDKN2A/2B (rs10811661) was associated with T2DM [45]. SNP 
rs10811661 located 125 kb upstream of the CDKN2B and CDKN2A genes, has been 
associated with T2DM in three of the GWA studies (OR for pooled studies 1.20 [95% CI 
1.14–1.25], P=5×10−15) [19, 20, 24]. And the association was confirmed in Danish, Norwegian, 
French, Korean, Japanese and Chinese participants [10–15]. In murine models studies 
suggest that the rs10811661 polymorphism located upstream of the CDKN2B and CDKN2A 
genes may confer increased risk for T2DM by affecting ǃ cell function [46-48].  
1.1.2.3 CDC123/CAMK1D 
SNP rs12779790 is located ~90 kb from cell division cycle 123 homolog [S. cerevisiae] 
(CDC123) gene and~63.5kb from calcium/calmodulin-dependent protein kinase I delta 
(CAMK1D) gene. CDC123 gene encodes a protein involved in cell cycle regulation and 
nutritional control of gene transcription [23, 49]. CAMK1D regulates granulocyte function 
[50], it is also possible that a causative variant in this region is related to CAMK1D and 
affects pancreatic ǃ-cell function through increased apoptosis. SNP rs12779790 is found 
associated with T2DM in several studies. G risk allele of rs12779790 was associated with a 
lower insulin genic index, corrected insulin response, and area under the insulin/glucose 
curve during OGTTs and a lower DI in carriers of the G allele [51]. In Asian Indian descent 
subjects also found the ǃ-cell defect [34]. Trend toward lower ǃ-cell function could be 
observed in Caucasians population [35, 38, 52]. SNP rs12779790 variation carriers showed a 
lower insulin response to glucose stimulation and noted a trend toward a reduced insulin 
response after arginine stimulation. Arginine stimulation during hyperglycemia is a 
measure of (near) maximal insulin secretion and has been suggested as a proxy for ǃ-cell 
mass. This gene variant affected ǃ-cell function by causing reduced ǃ-cell mass due to 
enhanced apoptosis [50].  
1.1.3 Genes involved in gene transcription 
1.1.3.1 TCF2 
The SNPs rs7501939 and rs4430796 on 17q12 are located in the first and second intron of the 
transcription factor 2 isoform b (TCF2) gene, respectively [53]. One of the variants is in TCF2 
(HNF-1┚), a gene known to be mutated in individuals with maturity-onset diabetes of the 
young type 5 [54]. SNPs in TCF2 are also associated with both T2DM and prostate cancer 
[53, 54]. Three genes with common variants that influence risk of T2DM were first 
discovered based on rare Mendelian mutations (KCNJ11, WSF1 and TCF2). This is 
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particularly interesting given the recent finding that SNPs in TCF2 are also associated both 
with T2DM and prostate cancer [53, 54].  
1.3.2 TCF7L2 
Transcription factor 7-like 2 (TCF7L2) gene encodes a transcription factor (Tcf-4) which 
involved in the regulation of cellular proliferation and differentiation [55]. TCF7L2 plays an 
important role in the Wnt signaling pathway. TCF7L2 is involved in the growth, 
differentiation, proliferation, and insulin secretion of pancreatic ǃ-cells [56]. GWA studies 
found variants in the TCF7L2 showed to be associated with an increased risk for T2DM [19, 
20, 22, 23, 25, 57]. The strongest associations with T2DM with a clear gene dose effect were 
reported for the rs7903146 variant [58]. TCF7L2 was found to be associated with less weight 
loss in response to lifestyle intervention [59]. Genetic variants in the exon 4 (including 
rs7903146) block of TCF7L2 were associated with impaired insulin secretion and incident 
diabetes in a prospective Chinese cohort [60]. TCF7L2 gene polymorphism also affected the 
drug response for T2DM therapy which was the only predictor of sulfonylureas treatment 
failure [61]. The rs7903146 T-allele conferred a higher risk for sulfonylurea treatment failure 
[61]. It has been observed that homozygous carriers of the TCF7L2 risk alleles (rs1225372 
and rs7903146) were twice as likely not to respond to sulfonylureas as patients homozygous 
for the non-risk alleles [62].  
1.1.3.3 HHEX 
GWA studies identified that the haematopoietically expressed homeobox (HHEX) gene 
polymorphism was a risk of T2DM in several populations [19-25]. HHEX encodes the 
transcription factor hematopoietically expressed homeobox protein, which is expressed in 
the embryonic ventral-lateral foregut that causes the ventral pancreas and the liver [63]. It 
has been confirmed the significant association of HHEX with T2DM in the Japanese 
population [64]. HHEX was a common T2DM-susceptibility gene across different ethnic 
groups. The OR values of the three SNPs rs1111875, rs5015480 and rs7923837 genotyped in 
HHEX (1.20–1.46) were higher in Japanese than those of the European population (1.20) [64]. 
HHEX variant was associated with impaired proinsulin conversion [38]. SNP rs1111875 and 
rs7923837 was associated with T2DM independent of body fat [65]. SNP rs7923837 in the 3’-
flanking region of the HHEX locus was associated with altered glucose-stimulated insulin 
release. This SNP’s major allele represented a risk allele for ǃ-cell dysfunction and might 
confer increased susceptibility of ǃ-cells toward adverse environmental factors [66]. 
Knockout of HHEX gene showed impair proliferation of endodermal epithelial cells, 
positioning of ventral foregut endoderm cells relative to the mesoderm, and budding and 
morphogenesis of the ventral pancreas [63]. This genetic manipulation finally provoked 
lethality during midge station [63]. 
1.1.3.4 JAZF1 
The juxtaposed with another zinc finger gene 1 (JAZF1) gene encodes a transcriptional 
repressor of nuclear receptor subfamily 2, group C, member 2 (NR2C2) with three C2H2-
type zinc fingers [67]. Mice deficient in Nr2c2 exhibit growth retardation, low IGF1 serum 
levels, and perinatal and early [53, 54] stnatal hypoglycaemia [68]. JAZF1 is expressed in 
pancreas, brain, thalamus, liver, uterus, endometrial and prostate. In a meta-analysis in 
East Asians, it has been found that the variant of JAZF1 rs864745 was significantly 
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associated with T2DM [69]. SNP rs864745 is in intron 1 of the JAZF1 gene. The major T-
allele of the rs864745 conferring increased diabetes risk was associated with increased 2nd 
phase serum insulin release during an IVGTT, and an increased fasting serum insulin 
level [69]. Carriers of the diabetes-associated T-allele of rs864745 had an allele dependent 
3% decrease in BIGTT-AIR. JAZF1 is expressed in the pancreas [67], one might speculate 
that a gain-of-function variant in JAZF1 may lead to postnatal growth restriction also 
affecting pancreatic ǃ-cell mass and function [51]. SNP rs864745 in JAZF1 were 
significantly associated with traits of insulin secretion in a glucose-tolerant Danish 
population [51].  
1.1.4 Others  
1.1.4.1 PPAR-γ2 
Peroxisome proliferator-activated receptor-Ǆ2 (PPAR-Ǆ2) is one of PPAR-Ǆ isoforms and is a 
member of the nuclear hormone receptor subfamily of transcription factors, which regulates 
transcription of various genes [70]. PPAR-┛ plays an important role in adipocyte 
differentiation, regulating glucose, and lipid homeostasis [70]. Pro12Ala is one of important 
polymorphism in codon 12 of exon B causing proline-to-alanine change [71]. The Ala allele 
reduces the transcriptional activity of PPAR-Ǆ2 and may protect against T2DM compared 
with the more common Pro/Pro genotype [72, 73]. The effects of the PPAR-Ǆ2 Pro12Ala 
polymorphism on glucose and insulin metabolism may be modified by prenatal exposure to 
famine during midge station [74]. Patients with the Pro12Ala genotype had a better 
therapeutic response to rosiglitazone than the Pro12Pro genotype subjects. The genetic 
variations in the PPAR-Ǆ2 gene can affect the response to rosiglitazone therapeutic efficacy 
in T2DM patients [75]. 
1.1.4.2 IGF2BP2 
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) belongs to an mRNA-
binding protein family that plays role in RNA localization, stability and translation [76]. 
IGF2BP2 is highly expressed in pancreatic islets and binds to insulin-like growth factor 2 
(IGF-2), which is an important growth and insulin signaling molecule [24]. IGF2BP2 is a 
homolog of IGF2BP1, which binds to the 5’UTR of IGF2 mRNA and regulates IGF2 
translation [77]. Several GWA studies have found that subjects carrying mutant alleles of 
SNPs rs1470579 and rs4402960 in IGF2BP2 gene showed a moderately increased risk of 
T2DM. Several studies have confirmed this result in Asian populations [30, 57, 78, 79]. 
T2DM patients with different IGF2BP2 genotypes showed various levels of insulin secretion. 
It has been demonstrated that variants in IGF2BP2 gene affect first-phase insulin secretion 
and the disposition index detected by hyperglycemic clamps [80].  
Interactions between genetic variation in IGF2BP2 and T2DM maybe exerted through this 
IGF2 pathway and through the insulin pathway. The IGF2BP2 gene is located at chromosome 
3q27.2. Intron 2 is the longest intron among mammalian species. SNPs rs1470579 and 
rs4402960 are located in a 50-kb region of this intron. Diabetes-predisposing variants may 
affect regulation of IGF2BP2 expression [20]. The IGF2BP2 gene variant (rs4402960) was 
associated with insulin sensitivity, FPG, glucose AUC, and FPG [81]. SNP rs4402960 was also 
associated with reductions in first-phase insulin secretion and in the disposition index, which 
reflected the failing adaptive capacity of pancreatic ǃ-cells [80] resulting in hyperglycemia 
including FPG and PPG. SNP rs4402960 has also been shown to be associated with the 
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disposition index in Hispanic Americans [82], HOMA-ǃ in non-diabetic Japanese individuals 
and lower acute insulin release and tolerance [64]. SNP rs4402960 is strongly associated with 
an increased risk of T2DM and increased AUC of glucose in individuals of Dutch descent [83]. 
Wu et al observed a significant association of SNPs (rs1470579 and rs4402960) in IGF2BP2 [1.17 
(1.03–1.32); P=0.014] with combined IFG (impaired fasting glycemia)/T2DM group. The 
association of these SNPs with HOMA-ǃ reduction suggested that IGF2BP2 gene confers 
T2DM risk through a reduction of ǃ-cell function [30]. Another study in Chinese T2DM 
population according with these results and found IGF2BP2 variations effect on the 
therapeutic efficacy of repaglinide treatment in Chinese T2DM patients. Patients with the 
rs1470579 AC+CC genotypes had poor responses to repaglinide treatment with respect to FPG 
and PPG compared with individuals with the AA genotype. Patients with the GT+TT 
genotypes of rs4402960 also showed a better repaglinide therapeutic effect on PINS compared 
with individuals with the GG genotype. Replication of this research has indicated that 
IGF2BP2 variants were more likely to be associated with reduced ǃ-cell function [80, 84]. 
IGF2BP2 was shown to affect insulin secretion in a previous study. Understanding the 
biological mechanism by which variants in IGF2BP2 could mediate these effects on the 
biphasic pattern of insulin secretion will require further investigation. 
1.1.4.3 FTO 
Fat mass and obesity associated (FTO) gene was found in a GWA study for T2DM 
susceptibility genes identified and showed to predispose to diabetes through an effect on 
BMI [85]. SNPs rs9939609 in the FTO gene region on chromosome 16 was strongly 
associated with T2DM [85]. A number of SNPs in tight linkage disequilibrium with 
rs9939609, and residing in the first intron of the FTO gene, had been associated with obesity 
in large populations of adults and children. It had been showed that common variation 
rs9939609 was reproducibly associated with BMI and obesity from childhood into old age 
[86]. And recently it has been identified T2DM risk variants only the risk variant of the FTO 
gene (rs8050136) showed statistically significant association with BMI, FMI, and Waist 
Circumferences [87] .Some data indicated that FTO SNP rs9939609 was associated with 
differences in BMI, with the presence of the A allele linked to a greater risk of increased BMI 
and increased values for specific measures of adiposity, such as the sum of skin fold values 
and total body water as assessed by isotope analysis [88]. 
1.1.4.4 THADA 
THADA (thyroid adenoma associated) gene encodes thyroid adenoma–associated protein 
may involve in the death receptor pathway and apoptosis [89]. Disruption of THADA by 
chromosomal rearrangements (including fusion with intronic sequence from PPAR-Ǆ) is 
observed in thyroid adenomas [90]. The function of THADA has not been well-
characterized, but there is some evidence to suggest that it may be involved in the death 
receptor pathway and apoptosis [89, 91]. The THADA gene variant was also associated with 
lower ǃ-cell response to GLP-1 and arginine, suggested lower ǃ-cell mass as a possible 
pathogenic mechanism [92]. SNP rs7578597 was a non-synonymous SNP causing threonine 
to alanine in 1187 position which strongly associated with T2DM (combined OR [95%CI] of 
1.15[1.10-1.20], P=1.1×10−9) resided in exon 24 of THADA gene[23]. Subjects with the 
rs7578597 (T1187A) gene variant in THADA had a reduced ǃ-cell mass due to increased 
apoptosis [92]. Analyses in the control subjects showed that THADA SNP rs7578597 was 
association with 2-h insulin during oral glucose tolerance tests [93]. 
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1.1.4.5 TSPAN8/ LGR5 
Tetraspanin 8 is a cell-surface glycoprotein, widely expressed cell surface glycoprotein 
known to form complexes with integrins to regulate cell motility in cancer cell lines [23, 94]. 
Tetraspanin 8 gene (TSPAN8) polymorphism rs7961581 was one of the strongest statistical 
signals associated with T2DM. SPAN8/LGR5 rs7961581 was significantly associated with 
T2DM in a meta-analysis in East Asians [69]. SNP rs7961581 associated with decreased 
levels of CIR, of AUC-insulin/AUC-glucose ratio, and of the insulinogenic index [51]. SNP 
rs7961581 resided ~110 kb upstream of TSPAN8 gene. Because 6-integrin binding to laminin 
had been shown to negatively affect pancreatic ǃ-cell mass maintenance [95], it was possible 
that variation in TSPAN8 influenced pancreatic ǃ-cell function.  
1.1.4.6 ADAMTS9 
ADAMTS9 is a member of the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) protein family which has been implicated in the cleavage of 
proteoglycans [96], the control of organ maturation, development [97] and inhibition of 
angiogenesis [98]. ADAMTS9 is a secreted metalloprotease that cleaves the proteoglycans 
versican and aggrecan, and is expressed in skeletal muscle and pancreas [23]. SNP rs4607103 
in ADAMTS9 gene representing a cluster of associated SNPs, resides ~38 kb upstream of the 
ADAMTS9 gene, and also associated with T2DM susceptibility [52]. It has been found 
common diabetes-related C allele of rs4607103 at chromosome 3p14.3-2 upstream of 
ADAMTS9 was associated with a decrease in insulin sensitivity of peripheral tissues, as 
estimated from a euglycemichy perinsulinemic clamp [69]. And impairment of insulin 
sensitivity occurred in the presence of an increase in serum insulin levels in response to 
intravenous and oral glucose loads [69]. The major C-risk allele of rs4607103 near ADAMTS9 
conferred increased risk of T2DM, associated with increased fasting plasma glucose levels 
and reduced insulin-stimulated glucose uptake during a euglycemic-hyperinsulinemic 
clamp. The C-risk allele also showed statistically significant associations with increased 
levels of serum insulin at 30 min after oral ingestion of glucose as well as with increased first 
and second phase serum insulin release as estimated from an IVGTT [99]. 
1.1.4.7 NOTCH2 
Notch 2 (Notch homolog 2 [Drosophila]) expresses when pancreatic buds branch and is 
restricted to embryonic ducts, should be the source for endocrine and exocrine stem cells in 
mice [23, 100]. Notch pathway plays key role in dictating endocrine differentiation. Activation 
of this pathway is critical for the maintenance of the progenitor pool between the first and 
second transitions of pancreatic development [101]. NOTCH2 is a type 1 transmembrane 
receptor. The SNP rs10923931 residing in intron 5 of the NOTCH2 gene strongly associate with 
T2DM susceptibility. SNP rs10923931 is near complete linkage disequilibrium with SNP 
rs2641348 in the ADAM30 gene [23]. Rs2641348, a non-synonymous SNP (L359P) within the 
neighboring ADAM metallo-peptidase domain 30 gene (ADAM30) represented the same 
signal (r2=0.92 based on HapMap CEU data) and was also followed-up. 
1.1.4.8 PTPRD 
A GWA study in Chinese population identified two genes, PTPRD and SRR, which were not 
previously described to be involved in diabetes or glucose metabolism [102]. PTPRD is the 
protein tyrosine phosphatase receptor type D gene and widely expressed in skeletal muscle, 
pancreas, and brain which belong to the receptor type IIA (R2A) subfamily of protein 
tyrosine phosphatases (PTPs). The R2A PTP subfamily comprises leukocyte common 
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antigen-related (LAR), protein tyrosine phosphatase sigma (PTPRS), and PTPRD. The R2A 
family has been implicated in neural development, cancer, and diabetes [103]. PTPRD-
deficient mice exhibited impaired learning and memory, early growth retardation, neonatal 
mortality, posture and motor defects [104]. LAR- and PTPRS-deficient mice showed 
defected glucose homeostasis and insulin sensitivity [105-107]. Transgenic mice over 
expressing LAR in skeletal muscle showed whole-body insulin resistance [108]. R2A 
subfamily members have similar structure [109]. PTPRD could act in T2DM pathogenesis 
and affect insulin signaling on its target cells. But it need further 
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Intron 2
/
/
[53]
[53]
17q12 
WSF1 
 
 
 
rs10010131
rs752854 
rs6446482 
rs734312 
Intron
Intron 
Intron 
Exon 
/
/ 
/ 
H61R 
[40]
[37] 
[37] 
[37] 
4p12 
TCF7L2 rs7903146 Exon 4 [58] 10q25.3 
HHEX 
 
 
rs1111875
rs5015480 
rs7923837 
3’-UTR
? 
? 
/
/ 
/ 
[20]
[20] 
[20] 
 
 
SLC30A8 rs13266634 Exon 8 R325W [25] 8q24.11 
CDKAL1 
 
 
 
rs7756992
rs7754840 
rs9465871 
rs10946398
Intron 5
? 
? 
?
/
/ 
/ 
/
[22]
[118] 
[30] 
[30]
6p22.3 
 
CDKN2A-2B rs10811661 ? / [19] 9p21 
IGF2BP2 
 
rs1470579
rs4402960 
Intron 2
Intron 2 
/
/ 
[20]
[20] 
3q27.2 
 
FTO rs8050136 Intron / [87] 16q12.2 
 rs9939609 Intron 1 [86]
JAZF1 rs864745 Intron 1 / [23] 7p15.2-p15.1 
CDC123/CAMK1D rs12779790 ? / [23] 10p13 
THADA rs7578597 Exon 24 T1187A [23] 2p21 
TSPAN8 rs7961581 ? / [23] 12q14.1-q21.1 
ADAMTS9 rs4607103 near / [23] 3p14.3-2 
NOTCH2 rs 10923931 Intron 5 / [23] 1p13-p11 
PTPRD rs17584499 Intron 10 / [102] 9p24.1-p23 
SRR rs391300 [102] 17p13.3 
 rs4523957 [102]
KCNQ1 rs2237892 Intron 15 / [23] 11p15.5 
 
 
rs2237895
rs2237897 
rs2283228 
rs151290
Intron 15
Intron 15 
Intron 15 
Intron 15
/
/ 
/ 
/
[23]
[23] 
[11] 
[17]
 
 
Table 1.1 Summary of associated genes 
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characterize. PTPRD gene polymorphism rs17584499 showed significant association with 
T2DM (P = 8.54610-10; odds ratio [OR] = 1.57; 95% confidence interval [CI] = 1.36–1.82) [102]. 
This SNP locates in intron 10. 
1.1.4.9 SRR 
SRR (serine racemase) gene encodes aserine racemase that synthesizes D-serine from L-
serine [110, 111]. D-serine (co-agonist) and the neurotransmitter glutamate bind to the N-
methyl Daspartate (NMDA) receptors and trigger excitatory neurotransmission in the brain 
[102, 112, 113]. NMDA receptor activation requires binding of glutamate and D-serine, 
which plays a neuromodulatory role in NMDA receptor transmission, synaptic plasticity, 
cell migration, and neurotoxicity [62]. D-serine and SRR express in the pancreas [114]. 
Glutamate signaling has function involved in positively regulates insulin and glucagon 
secretion in pancreatic islets [115-117]. Thus, SRR and D-serine may play roles in the 
etiology of T2DM. SNPs rs391300 and rs4523957 in the SRR gene were associated with 
T2DM in a Han Chinese GWA study. SNPs rs391300 and rs4523957 were in tight LD with 
each other (r2 = 0.942 in HapMap HCB)[102]. The nearby SNP rs216193 also showed 
significant association; this SNP resides 3.8 kb upstream from SRR. SNP rs216193 was in 
tight LD with rs391300 (r2 = 0.942 in HapMap HCB) [102]. 
2. Anti-diabetic drugs pharmacogenetics 
2.1 Insulin secretagogue agents ------sulfonylureas (SUs) 
The sulfonylurea anti-diabetic agents are insulin secretogogues including the first 
generation sulfonylureas (acetohexomide, chlorpropamide, tolazamide and tolbutamide) 
and second generation sulfonylureas (glibenclamide (glyburide), glipizide, gliclazide, and 
glimepiride) which are most widely used for T2DM treatment by closing the pancreatic ǃ-
cell potassium channels and stimulation insulin secretion [119].  
2.1.1 Cytochrome P450  
Sulfonylurea hypoglycemic agents are metabolized by cytochrome P450 2C9 (CYP2C9) 
enzyme. Genetic polymorphisms Arg144Cys (CYP2C9*2) and Ile359Leu (CYP2C9*3) could 
affect the safety and efficacy of sulphanylureas drugs in T2DM patients [120]. CYP2C9 
genotypes significantly affected glyburide pharmacokinetics. Carriers with CYP2C9 variant 
*3 had decreased oral clearances [121]. Suzuki et al reported the subjects with CYP2C9*3 
alleles showed the metabolic activity decrease of glimepiride hydroxylation and a marked 
elevation in the plasma concentrations of glimepiride, compared with subjects with a 
CYP2C9*1/*1(wild type). The elevated glimepiride concentrations in subject with 
CYP2C9*1/*3 may increase the pharmacological effects [122]. Zhang et al reported the 
pharmacokinetics of gliclazide modified release were affected mainly by CYP2C19 genetic 
polymorphism in healthy Chinese subjects [123].  
2.1.2 Sulfonylurea receptor 
The sulphonylurea receptor is a subunit of the ATP-sensitive potassium channel located in 
pancreatic ǃ-cell. The variants in the exon 16 -3C/T variant (rs1799854) of SUR1 
(Sulfonylurea Receptor 1) was associated with T2DM and 25% reduction in second-phase 
insulin secretion in -3T allele carriers in Dutch subjects with normal glucose tolerance (NGT) 
and impaired glucose tolerance (IGT) [124]. The association also found in Japanese [125] and 
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Finnish population [126]. A recent publication reported genotyped 25 SNPs from 661 
Chinese T2DM patients who received 8 weeks of gliclazide therapy. The subjects with GG 
genotype in SUR exon 33(S1369A, rs757110) had a 7.7% greater decrease in FPG and 11.9% 
greater decrease in HbA1c after 8 weeks of gliclazide therapy [127].  
2.1.3 Others 
It was described that the exon 33 of the ABCC8 (rs757110) and KCNJ11 (rs5210) genes 
were associated with gliclazide antidiabetic efficacy [127]. SNPs of TCF7L2 had been 
consistently associated with T2DM in different ethnic descent and also had great impact 
on the T2DM patients’ response to sulfonylureas [128]. The Go-DARTS2 study reported 
that the T allele of rs7903146 was associated with increased HbA1c in both cases and 
controls [129]. The same study group revealed that carriers of TCF7L2 variants were more 
likely to fail sulfonylurea therapy but not metformin (HbA1c > 7 %) within 3-12 months of 
treatment initiation [62]. 
Hepatocyte nuclear factor-1ǂ (HNF-1ǂ) is a homeodomain-containing transcription factor 
that expressed in the pancreatic ǃ-cell and HNF-1ǂ SNPs have been associated with ǃ-cell 
dysfunction and maturity onset diabetes of the young (MODY) [130]. Variations in HNF-1ǂ 
polymorphisms of T2DM were reported to be more sensitive to the hypoglycaemic effects of 
sulfonylureas [131-133]. Pearson et al reported that patients with HNF-1ǂ polymorphisms 
(P129T, E132K, R159W, R229P, W267R and P291fsinsC) had a 5.2-fold greater response to 
gliclazide than to metformin and 3.9-fold greater response to gliclazide than patients 
without HNF-1ǂ mutations [134]. 
2.2 Insulin secretagogue agents ------ Non-sulfonylureas  
Meglitinides (repaglinide and nateglinide) represent a new class of insulin secretagogue, 
structurally unrelated to sulphanylureas by very rapid onset and abbreviated duration of 
action [135]. Meglitinides stimulate first-phase insulin release in a glucose-sensitive manner 
and reduce the risk of hypoglycemic events. 
2.2.1 Cytochrome P450 and transporters 
Repaglinide is metabolized by CYP2C8 and CYP3A4 [136]. The CYP2C8*3 variant 
(Arg139Lys, Lys399Arg) allele was associated with reduced plasma concentrations of 
repaglinide [137]. Repaglinide mean AUC and maximium plasma concentration (Cmax) were 
45 and 39 lower, respectively, in subjects with the CYP2C8*1/*3 genotype compared with 
wild-type homozygotes. Repaglinide AUC was also 13% lower in subjects with the 
CYP2C8*1/*4 genotype compared with wild-type homozygotes, although this was not 
statistically significant [137]. Genetic polymorphisms of CYP3A4, specifically CYP3A4*18, 
played a major role in contributing to the inter-individual variability in repaglinide’s 
pharmacokinetics [138]. 
The oral bioavailability of nateglinide is about 73%, and it is rapidly absorbed and 
extensively metabolized primarily by CYP2C9 in the liver and a smaller fraction by CYP3A4 
and CYP2D6 [139]. Nateglinide is confirmed as a substrate of CYP2C9. A previous report 
showed that the CYP2C9*3 allele was associated with significantly reduced oral nateglinide 
clearance and pharmacokinetic parameters, which seemed to be unaffected by CYP2C9*2 
and CYP2D6*4 or *5 carriers [140].  
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The meglitinide class drug nateglinide is metabolized by CYP2C9. According to 
pharmacokinetic data, moderate dose adjustments based on CYP2C9 genotypes may help in 
reducing interindividual variability in the anti hyperglycemic effects of nateglinide [173].  
Carriers of the CYP2C9*3/*3 genotype may be at a slightly higher risk of hypoglycemia 
compared to carriers of CYP2C9*1, particularly when taking nateglinide doses above 120 mg 
[140].  
Polymorphic organic anion transporting polypeptide 1B1 (SLCO1B1) is a major determinant 
of repaglinide pharmacokinetics [141]. SLCO1B1 (which codes the OATP1B1 gene, also 
known as OATP-C, OATP2) polymorphisms are important predictors of repaglinide 
pharmacokinetics [141]. Repaglinide AUC was 60–110% greater in participants with the 
c.521CC genotype than in those with the c.521TT genotype after ingestion of single 
repaglinide doses ranging from 0.25 to 2mg [142]. Haplotypes of SLCO1B1*1b/*1b (c.388 G–
c.521 T) was associated with reduced pharmacokinetic exposure after a single dose oral 
administration of 2 mg repaglinide, including decreased AUC0-∞ and increased clearance 
of repaglinide [143]. 
2.2.2 Others  
An association of (IGF2BP2) rs1470579 and rs4402960 polymorphisms and development of 
T2DM and therapeutic efficacy of repaglinide in Chinese T2DM patients was reported. The 
effects of the repaglinide treatment on FPG (P<0.05) and PPG (P<0.05) were reduced in 
patients with the rs1470579 AC+CC genotypes compared with AA genotype carriers. 
Patients with the rs4402960 GT+TT genotypes exhibited an enhanced effect of repaglinide 
treatment on PINS (P<0.01) compared with GG genotype subjects [144]. SLC30A8 
rs13266634 and rs16889462 polymorphisms were associated with repaglinide therapeutic 
efficacy in Chinese T2DM patients. There were significantly augmented repaglinide effects 
in patients with rs13266634 CT+TT genotypes on FINS and PINS compared with rs13266634 
CC genotype. And patients with rs16889462 GA genotype showed enhanced repaglinide 
effects on FPG, PPG, and HbAlc compared with GG genotype [31]. Variations in the neural 
nitric oxide synthase adaptor protein (NOS1AP) involved in insulin secretion and insulin 
signal pathway may explain some of the variability in response to anti-diabetic drug. A 
common variant in rs10494366 was associated with repaglinide monotherapy efficacy on 
insulin resistance in newly diagnosed Shanghai Chinese T2DM patients [145].  And sheng et 
al study suggested that NAMPT -3186C>T polymorphism was significantly associated with 
plasma levels of PINS and CHO in Chinese T2DM patients with repaglinide monotherapy 
[146]. KCNQ1 polymorphism rs2237892 was associated with repaglinide’s efficacy on 
improving insulin sensitivity in Chinese patients with T2DM [15]. 
2.3 Biguanides 
Metformin (a biguanide) is among the most widely prescribed drugs and has a gluco-
regulator effect in the presence of endogenous insulin by reducing gastrointestinal glucose 
absorption, decreasing endogenous glucose production and reducing peripheral resistance 
to insulin [147]. 
2.3.1 Transporters 
Organic cation transporter 1 (OCT1, gene name SLC22A1) is the major mechanism for 
metformin entry into hepatocytes and enterocytes [148]. Human OCT1 is highly 
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polymorphic. Shu’ study provided proof of concept that genetic variation in OCT1 may be 
associated with variation in response to metformin OCT1 Met420del had reduced activity 
for metformin [149]. Another study in healthy subjects also confirmed polymorphisms in 
OCT1 were associated with the renal clearance of metformin [150]. Low-function OCT1 
amino acid substitutions Arg61Cys, Ser401Gly, Met420del, and Gly465Arg, and the OCT1 
promoter-linked variant rs1867351, were associated with an increase in the renal clearance 
of metformin by~20% and ~30%, respectively. These data suggested that a reduction in 
OCT1 expression or activity may increase renal excretion of metformin [150]. But in T2DM 
patients, the OCT1 loss-of-function variants, Arg61Cys and Met420del, did not attenuate the 
HbA1C reduction achieved by metformin [151]. 
2.3.2 Others 
Recently, serine-threonine kinase 11 (STK11), which phosphorylates AMPK, has also been 
reported to be involved in metformin effects. The STK11 rs8111699 SNP influenced insulin 
sensitivity and metformin efficacy [152]. Schroner et al showed that the degree of reduction 
in HbA1c and FPG after ulphonylurea treatment in addition to previous metformin 
monotherapy was related to TCF7L2 gene polymorphisms [153]. ATM, a gene known to be 
involved in DNA repair and cell cycle control, played a role in the effect of metformin 
upstream of AMP-activated protein kinase, and variation in this gene altered glycemic 
response to metformin [154]. 
2.4 Euglycemic agents  
Thiazolidinediones (pioglitazone, rosiglitazone) are insulin sensitizing agents and have 
glucose and lipid lowering activity. They are selective agonists for the PPAR-Ǆ and decrease 
insulin resistance and enhance the biological response to endogenously produced insulin.  
2.4.1 Cytochrome P450 
Both rosiglitazone and pioglitazone are extensively metabolized in the liver by CYP2C8 
[155, 156]. Kirchheiner and colleagues considered the influence of the CYP2C8*3 
polymorphism on single dose and multiple-dose rosiglitazone (8 mg) pharmacokinetics in 
German healthy volunteers [157]. Tornio et al evaluated the effects of the CYP2C8*3 allele on 
single-dose pioglitazone (15 mg) pharmacokinetics in healthy volunteers [158]. The weight-
adjusted pioglitazone AUC was 34% lower in CYP2C8*3 homozygotes and 26% lower in 
heterozygotes compared with wild-type homozygotes (P < 0.05, both comparisons). The 
half-life of pioglitazone was significantly shorter in heterozygotes (3.4 h) and CYP2C8*3 
homozygotes (3.3 h) compared with wild-type homozygotes (4.5 h). Daily et al reported 
following a single dose of rosiglitazone 4 mg, mean AUC was 29% lower and weight-
adjusted oral clearance was 39% higher in heterozygotes compared with wild-type 
homozygotes [159]. 
2.4.2 Others 
Rosiglitazone improves insulin sensitivity by reducing plasma glucose levels and serum 
insulin, NEFA and triglyceride and by increasing HDL cholesterol levels [160, 161]. 
Vestergaard et al reported rosiglitazone treatment, in combination with insulin and 
metformin, of patients with severe primary insulin resistance due to IR mutations and 
diabetes mellitus, had no impact on the measured estimates of glucose and lipid 
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metabolism [162]. It was found that variations SNP45 and SNP276 in the adiponectin gene 
could affect the rosiglitazone treatment response to the serum adiponectin level and blood 
glucose control [158]. Sun et al reported that the adiponectin allele 45T/G and -11377C/G 
polymorphisms were significantly associated with the therapeutic efficacy of multiple-
dose rosiglitazone in Chinese patients with T2DM [163]. And TNF-┙ G-308A 
polymorphism might be associated with the therapeutic efficacy of rosiglitazone in T2DM 
patients [164]. Genetic variations 11482G/A in the perilipin gene could affect weight gain 
associated with rosiglitazone treatment in patients with T2DM [165]. Brunham et al 
demonstrated that the ATP-binding cassette transporter subfamily A number 1 (ABCA1) 
probably had an effect on islet cholesterol homeostasis, and influencing glucose tolerance 
and insulin secretion [166]. The 219K variant of ABCA1 gene was associated with the 
therapeutic effect of rosiglitazone. The RR homozygotes had a better response to 
rosiglitazone treatment in terms of insulin sensitivity improvement than minor K allele 
carriers [167]. The genetic variations in the PPAR-┛2 gene could affect the response to 
rosiglitazone treatment in patients with T2DM. Patients with the Pro12Ala genotype in 
the PPAR-┛2 gene had a better therapeutic response to rosiglitazone than did patients 
with the Pro12Pro genotype [75]. LPIN1 genetic variations rs10192566 could affect 
rosiglitazone treatment response in T2DM [168]. Zhang et al reptored carriers of A allele 
of Thr394Thr or Ser allele of Gly482Ser in PGC-1┙ gene showed a trend for poor 
therapeutic efficacy to rosiglitazone for A allele of Thr394Thr but a significant 
improvement in its effectiveness for Gly482Ser. Variants in PGC-1ǂ gene might impair the 
therapeutic efficacy of rosiglitazone [169]. 
Himelfarb et al investigated TNF-ǂ and IL-6 expression in leukocytes and their association 
with polymorphisms and bone markers in diabetic individuals treated with pioglitazone. 
TNF-┙ -308G>A polymorphism appeared to be involved in regulation of gene expression 
independently of hyperglycemia and its interaction with pioglitazone might modify tALP, a 
important bone marker. IL6 -174G>C variant was related with reduced risk of postprandial 
hyperglycemia but not with mRNA expression or bone markers [170]. The PPAR-┛ Pro12Ala 
gene polymorphism was associated with the response to pioglitazone in Chinese patients 
with T2DM [171]. Pioglitazone treatment had significantly beneficial effects on serum lipid 
profile and blood pressure in S447S genotype carriers. The S447X variant in lipoprotein 
lipase (LPL) gene might be a cause for therapy modification by pioglitazone [172]. 
3. Conclusion 
The rapidly increasing prevalence of T2DM is becoming a tremendous public health 
problem that affects more than 170 million patients worldwide. T2DM is a complex 
metabolic disorder with two major pathophysiological features: insulin resistance and 
pancreatic ǃ-cell dysfunction. The mechanism of this disease remains unknown; however, 
environmental factors and genetic variations are considered two major contributors to onset 
and development of T2DM. In this chapter, we introduced gene associated with T2DM, such 
as: KCNJ11, KCNQ1, SLC30A8, WSF1, CDKAL1, CDKN2A/B, TCF2, TCF7L2, HHEX, 
JAZF1, PPAR-Ǆ2, IGF2BP2, FTO, THADA, TSPAN8/ LGR5, ADAMTS9, NOTCH2, PTPRD, 
and SRR. Meanwhile, we described four anti-diabetic drugs pharmacogenetics, including 
insulin secretagogue agent sulfonylureas (SUs) and meglitinides, biguanides, and 
euglycemic agents. Genetic polymorphisms in drug-metabolizing enzymes, transporters, 
receptors, and other drug targets have been linked to interindividual differences in the 
www.intechopen.com
 
Pharmacogenetics for T2DM and Anti-Diabetic Drugs 
 
427 
efficacy and toxicity of a number of medications. Mutations in genes important in drug 
absorption, distribution, metabolism and excretion (ADME) play critical role in 
pharmacogenetics of diabetes. Numerous genes that influence pharmacogenetics of oral 
antidiabetics have been described. The investigations of genes associated with T2DM 
benefits of personalized medicine. And different types of genetic mutations and their 
influence on the response to therapy with oral antidiabetics are needed future study. 
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